We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Zachary A. Bogorad
Zachary A. Bogorad
Products
PRODUCTS
Bend Research, Inc.
Zachary A. Bogorad
and
Chiaochun J. Wang
Price:
$117.00
View
Botanic Beauty Products, Inc.
Zachary A. Bogorad
and
Christopher M. Jenner
Price:
$117.00
View
United States Department of Energy
Zachary A. Bogorad
,
Zachery L. Miller
,
Nayan J. Patel
, and
Zachary L. Stamm
Price:
$117.00
View
Optikem International, Inc.
Zachary A. Bogorad
Price:
$117.00
View
In Your Atmosphere Holdings
Zachary A. Bogorad
and
Nayan J. Patel
Price:
$117.00
View
Glaropharm AG
Zachary A. Bogorad
,
Vipulchandra Dhalakia
, and
Monica M. McClure
Price:
$117.00
View
BLA Enterprises dba Green Mountain Pharmacy
Zachary A. Bogorad
and
Tenzin Jangchup
Price:
$117.00
View
Sindan Pharma SRL
David D. Anderson
,
Zachary A. Bogorad
,
Lane V. Christensen
, and
Frank Wackes
Price:
$117.00
View
lnstitutt For Energiteknikk
Zachary A. Bogorad
Price:
$117.00
View
Actavis Italy S.p.A.
Zachary A. Bogorad
Price:
$117.00
View
View All Products by Zachary A. Bogorad
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More